P W Ind

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. ncbi request reprint Adjustable and fixed dosing with budesonide/ formoterol via a single inhaler in asthma patients: the ASSURE study
    P W Ind
    Respiratory Medicine, Clinical Investigation Unit, National Heart and Lung Institute, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Respir Med 98:464-75. 2004
  2. ncbi request reprint Safety of formoterol by Turbuhaler as reliever medication compared with terbutaline in moderate asthma
    P W Ind
    Respiratory Medicine Unit, ICSM at the National Heart and Lung Institute, Hammersmith Hospital, London, UK
    Eur Respir J 20:859-66. 2002
  3. ncbi request reprint Early clinical investigation of Viozan (sibenadet HCl), a novel D2 dopamine receptor, beta2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms
    P W Ind
    National Heart and Lung Institute, London, UK
    Respir Med 97:S9-21. 2003
  4. ncbi request reprint Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma
    P W Ind
    Hammersmith Hospital, DuCane Road, London, UK
    Respir Med 97:555-62. 2003
  5. ncbi request reprint Methotrexate therapy of oral corticosteroid-dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy
    C J Corrigan
    Guy s, King s and St Thomas, London, UK
    Clin Exp Allergy 35:579-84. 2005
  6. ncbi request reprint Concurrent therapy (long acting beta agonists and inhaled corticosteroids) in the management of asthma
    J A Saleh
    School of Postgraduate Medicine, Imperial College, Hammersmith Hospital, London
    Niger J Med 15:359-63. 2006
  7. ncbi request reprint Methotrexate therapy in asthma increases T cell susceptibility to corticosteroid inhibition
    C J Corrigan
    Guy s, King s and St Thomas Imperial College Schools of Medicine, London, UK
    Clin Exp Allergy 33:1090-6. 2003
  8. ncbi request reprint Sputum induction
    P L Paggiaro
    Cardiothoracic Dept, Cisanello Hospital, Pisa, Italy
    Eur Respir J Suppl 37:3s-8s. 2002
  9. ncbi request reprint Inhaled allergen-driven CD1c up-regulation and enhanced antigen uptake by activated human respiratory-tract dendritic cells in atopic asthma
    N E McCarthy
    Antigen Presentation Research Group, Imperial College London, Northwick Park and St Mark s Campus, Middlesex, UK
    Clin Exp Allergy 37:72-82. 2007
  10. ncbi request reprint COPD disease progression and airway inflammation: uncoupled by smoking cessation
    P W Ind
    Eur Respir J 26:764-6. 2005

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Adjustable and fixed dosing with budesonide/ formoterol via a single inhaler in asthma patients: the ASSURE study
    P W Ind
    Respiratory Medicine, Clinical Investigation Unit, National Heart and Lung Institute, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Respir Med 98:464-75. 2004
    ..Consistent with current guidelines, adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma control at reduced medication doses...
  2. ncbi request reprint Safety of formoterol by Turbuhaler as reliever medication compared with terbutaline in moderate asthma
    P W Ind
    Respiratory Medicine Unit, ICSM at the National Heart and Lung Institute, Hammersmith Hospital, London, UK
    Eur Respir J 20:859-66. 2002
    ..5 microg as needed was at least as safe, well tolerated and effective as terbutaline 0.5 mg in stable patients (requiring up to 6 relief inhalations x day(-1)) taking formoterol plus inhaled corticosteroids regularly over 12 weeks...
  3. ncbi request reprint Early clinical investigation of Viozan (sibenadet HCl), a novel D2 dopamine receptor, beta2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms
    P W Ind
    National Heart and Lung Institute, London, UK
    Respir Med 97:S9-21. 2003
    ..Sibenadet therapy was well tolerated with an adverse events profile comparable to current bronchodilator therapy. These data were viewed as extremely encouraging, warranting further, large-scale clinical investigation...
  4. ncbi request reprint Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma
    P W Ind
    Hammersmith Hospital, DuCane Road, London, UK
    Respir Med 97:555-62. 2003
    ..There was no evidence of tolerance and a low incidence of exacerbations in all treatment groups...
  5. ncbi request reprint Methotrexate therapy of oral corticosteroid-dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy
    C J Corrigan
    Guy s, King s and St Thomas, London, UK
    Clin Exp Allergy 35:579-84. 2005
    ..In a previous report, we showed that MTX increases T cell inhibition by CS. In this report we focus on effects of MTX on immunoglobulin concentrations and their possible clinical relevance...
  6. ncbi request reprint Concurrent therapy (long acting beta agonists and inhaled corticosteroids) in the management of asthma
    J A Saleh
    School of Postgraduate Medicine, Imperial College, Hammersmith Hospital, London
    Niger J Med 15:359-63. 2006
    ..Patients often require long-term anti-inflammatory and reliever drugs to achieve a normal life. This review aims to highlight role of concurrent therapy in the optimal management of asthma...
  7. ncbi request reprint Methotrexate therapy in asthma increases T cell susceptibility to corticosteroid inhibition
    C J Corrigan
    Guy s, King s and St Thomas Imperial College Schools of Medicine, London, UK
    Clin Exp Allergy 33:1090-6. 2003
    ..We hypothesized that MTX therapy of these patients increases the susceptibility of their T cells to corticosteroid inhibition...
  8. ncbi request reprint Sputum induction
    P L Paggiaro
    Cardiothoracic Dept, Cisanello Hospital, Pisa, Italy
    Eur Respir J Suppl 37:3s-8s. 2002
  9. ncbi request reprint Inhaled allergen-driven CD1c up-regulation and enhanced antigen uptake by activated human respiratory-tract dendritic cells in atopic asthma
    N E McCarthy
    Antigen Presentation Research Group, Imperial College London, Northwick Park and St Mark s Campus, Middlesex, UK
    Clin Exp Allergy 37:72-82. 2007
    ..Recent data suggest that CD1 antigen presentation by hRTDC may contribute to asthma pathogenesis...
  10. ncbi request reprint COPD disease progression and airway inflammation: uncoupled by smoking cessation
    P W Ind
    Eur Respir J 26:764-6. 2005